A Randomized Controlled Clinical Study of Peg-Rhg-CSF for Preventing Chemotherapy-Induced Neutropenia in Patients with B-Cell Non-Hodgkin Lymphoma

被引：0
|
作者：
Zhen, Changqing [1 ]
Ding, Mei [1 ]
Lu, Kang [1 ]
Ge, Xueling [1 ]
Chen, Na
Fang, Xiaosheng [1 ]
Sui, Xiaohui [1 ]
Jiang Yujie [1 ]
Liu, Xin [1 ]
Li, Ying [1 ]
Wang, Xianghua [1 ]
Li, Ying [1 ]
Zhang, Lingyan [1 ]
Xu, Hongzhi [1 ]
Fan, Juan [1 ]
Wang, Xin [1 ]
机构：
[1] Shandong Univ, Dept Hematol, Shandong Prov Hosp, Jinan, Peoples R China
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-128438
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5323
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer
    Zou, Dongling
    Guo, Mingfang
    Zhou, Qi
    BMC CANCER, 2021, 21 (01)
  • [22] Predicting the risk of chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphoma: Prospective risk model development.
    Dale, DC
    Crawford, J
    Wolff, D
    Agboola, O
    Culakova, E
    Lyman, GH
    BLOOD, 2003, 102 (11) : 305B - 305B
  • [23] A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer
    Dongling Zou
    Mingfang Guo
    Qi Zhou
    BMC Cancer, 21
  • [24] Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma
    Blasco, Helene
    Chatelut, Etienne
    de Bretagne, Isabelle Benz
    Congy-Jolivet, Nicolas
    Le Guellec, Chantal
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 (05) : 601 - 608
  • [25] Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma
    Meredith, Ruby F.
    Knox, Susan J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (02): : S15 - S22
  • [26] Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing granulocytopenia in sarcoma patients receiving doxorubicin combined with ifosfamide: A prospective, randomized, non-inferiority phase II study.
    Fan, Li
    Ye, Ting
    Wang, Zhongliang
    Cao, Rubo
    Wang, Bicheng
    Peng, Ling
    Chen, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] The Efficacy Research of Prophylactic PEG-rhG-CSF in Preventing Neutropenia in Early-Stage Breast Cancer Patients Treated With Docetaxel-Based Chemotherapy: A Retrospective Analysis
    Xing, Xueting
    Ding, Weijie
    Tang, Yongzhe
    Zhang, Jin
    Liu, Yamin
    Ning, Junhong
    Wang, Jie
    Zhang, Xiaoqing
    CLINICAL THERAPEUTICS, 2025, 47 (01) : 21 - 28
  • [28] Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma
    Lyman, Gary H.
    Poniewierski, Marek S.
    Culakova, Eva
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (04) : 483 - 492
  • [29] Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma
    Catarina Dias
    David A. Isenberg
    Nature Reviews Rheumatology, 2011, 7 : 360 - 368
  • [30] Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma
    Schulz, H.
    Bohlius, J.
    Skoetz, N.
    Trelle, S.
    Kober, T.
    Reiser, M.
    Dreyling, M.
    Herold, M.
    Schwarzer, G.
    Hallek, M.
    Engert, A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (04):
12345